Cue Biopharma Names Shao-Lee Lin as CEO to lead clinical-stage pivot toward immune tolerance and allergy programs with 2H2026...

Alvotech General Counsel Steps Down after six years, moving to board-level role at parent holding companies as company expands...

Revumenib transplant rate climbs to 48% in R/R KMT2A patients, enabling maintenance therapy as second revenue event for Syndax.

Rhythm's setmelanotide wins EU approval for acquired hypothalamic obesity, showing 19.8% placebo-adjusted BMI reduction at 52 weeks in the...

Novartis completes its $23B, seven-facility US manufacturing plan one year after launch — and the API strategy in North...

Pfizer's Elrexfio hits Phase 3 PFS goal in multiple myeloma, delivering statistically significant progression-free survival data for the bispecific...

Avalyn Pharma prices $300M Nasdaq IPO focused on respiratory drug reformulations, betting on de-risked development timelines and payer leverage.

BeOne secures option on HH160 trispecific antibody targeting PD-1, CTLA-4, and VEGF-A in $2B deal with Huahui Health.

AbbVie's $1.45B partnership with Plexium aims to develop RAS degraders using molecular glue chemistry to target hard-to-drug cancer mutations.

Chiesi acquires KalVista for $1.9B to add Ekterly, an oral on-demand treatment for hereditary angioedema, to its rare disease...